DISA Limited's (SGX:532) subsidiary, Digital Life Line, has partnered with the National University Hospital (Singapore) and the National University of Singapore to commercialize the Mobile Imaging Device for Anterior Segment (MIDAS), a portable cataract screening device, according to a Wednesday filing with the Tokyo Stock Exchange.
The AI-powered tool, designed for use with smartphones, enables quick, community-based cataract detection, targeting early intervention, the filing said.
Chief Executive Officer Eddie Chng said the device combines AI algorithms with ease of use, delivering results in 10 seconds. The company aims to expand the device's reach regionally.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。